MDCO The Medicines Company

32.71
+1.19  (+4%)
Previous Close 31.52
Open 31.63
Price To Book 68.15
Market Cap 2,595,540,037
Shares 79,350,047
Volume 1,066,933
Short Ratio
Av. Daily Volume 1,469,683

NewsSee all news

  1. Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates
  2. Is a Beat in Store for Melinta (MLNT) This Earnings Season?
  3. Edited Transcript of MDCO earnings conference call or presentation 24-Jul-19 12:30pm GMT
  4. Biotech Firm Wins Over Wall Street With Hopes for New Heart Drug
  5. Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due second half of 3Q 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Development discontinued due to poor effiacy - November 7, 2016.
MDCO-216 - MILANO-PILOT
Acute coronary syndrome (ACS)
Approved August 29, 2017.
Meropenem-vaborbactam
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Cangrelor
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
IONSYS
Acute postoperative pain
Approved August 6 2014 under priority review.
Oritavancin
ABSSSI
Phase 3 trial to be initiated 1H 2018.
Inclisiran
Homozygous familial hypercholesterolemia (HoFH)
Phase 3 data due second half of 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 data to be presented at ESC September 2, 2019 at 9:22 am CET.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 2 open-label data presented May 18, 2019. 51% decrease in LDL-C levels.
Inclisiran - ORION 3
Cardiovascular disease (ASCVD)

Latest News

  1. Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates
  2. Is a Beat in Store for Melinta (MLNT) This Earnings Season?
  3. Edited Transcript of MDCO earnings conference call or presentation 24-Jul-19 12:30pm GMT
  4. Biotech Firm Wins Over Wall Street With Hopes for New Heart Drug
  5. Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View
  6. Medicines Co (MDCO) Q2 2019 Earnings Call Transcript
  7. Medicines Co. (MDCO) Reports Q2 Loss, Lags Revenue Estimates
  8. The Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development Program
  9. The Medicines Co. to Host Earnings Call
  10. Are Insiders Buying The Medicines Company (NASDAQ:MDCO) Stock?
  11. David Einhorn's Greenlight Buys NeuBase Therapeutics Stake
  12. Melinta (MLNT) Announces Preliminary Product Sales for Q2
  13. The Medicines Company to Announce Second Quarter 2019 Financial Results on July 24
  14. The Medicines Company MDCO- 2019 Top Picks' Mid-Year Update
  15. Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran
  16. Notable Insider Buys This Past Week: AbbVie, MGM and More
  17. The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
  18. The Medicines Company Announces Pricing of Public Offering of Common Stock
  19. The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership
  20. The Medicines Company Announces Launch of Public Offering of Common Stock